Volume 32, Issue 12 (March 2022)
Studies in Medical Sciences 2022, 32(12): 886-894 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hajabbas Farshchi A, Valikhani A, Ghorbani S. The K562 Chronic Myeloid Leukaemia Cell Line undergoes Apoptosis in Response to 4-chloro-5-iodo-7H-pyrrolo[2.3-d]pyrimidine. Studies in Medical Sciences 2022; 32 (12) :886-894
URL: http://umj.umsu.ac.ir/article-1-5674-en.html
URL: http://umj.umsu.ac.ir/article-1-5674-en.html
M.Sc of Immunology, Department of Immunology, Urmia University, Urmia, Iran (Corresponding Author) , alirezafarshchi67@yahoo.com
Abstract: (2594 Views)
Background & Aims: Leukemia is a particular type of cancer characterized by the failure of cell death or disability in the differentiation of hematopoietic cells. Chronic myelogenous leukemia (CML) is the most studied kind of this type of cancer. In this study, the anti-cancer effect of the 4-chloro-5-iodo-7H-pyrrolo[2.3-d]pyrimidine compound on the human leukemia K562 cells was investigated.
Materials & Methods: The K562 cell line was cultured by initially seeding 1×106 cells per milliliter in RPMI 1640 medium. Cell viability was investigated using trypan blue exclusion and MTT assays. Cell death in cancer and normal cells was quantified using propidium iodide (PI) and acridine orange (AO) double staining. The one-way analysis of variance (ANOVA) and the SPSS16 and Excel softwares were used for data analysis. Data were analyzed statistically using the SPSS16 software. A probability level of p<0.05 was considered as the statistically significant reference.
Result: The 4-chloro-5-iodo-7H-pyrrolo[2.3-d]pyrimidine compound had a strong fatal and concentration-dependent effect on K562 cells and caused cell death mainly through induction of apoptosis. Statistical analysis of the cells under a fluorescence microscope revealed significant differences in apoptotic cell populations between treated and untreated cells.
Conclusions: The results of this investigation indicated that the 4-chloro-5-iodo-7H-pyrrolo[2.3-d]pyrimidine compound does have cytotoxic effects on the K562 cell line. This information also revealed that this compound may initiate a new therapeutic standpoint for the treatment of leukemia.
Materials & Methods: The K562 cell line was cultured by initially seeding 1×106 cells per milliliter in RPMI 1640 medium. Cell viability was investigated using trypan blue exclusion and MTT assays. Cell death in cancer and normal cells was quantified using propidium iodide (PI) and acridine orange (AO) double staining. The one-way analysis of variance (ANOVA) and the SPSS16 and Excel softwares were used for data analysis. Data were analyzed statistically using the SPSS16 software. A probability level of p<0.05 was considered as the statistically significant reference.
Result: The 4-chloro-5-iodo-7H-pyrrolo[2.3-d]pyrimidine compound had a strong fatal and concentration-dependent effect on K562 cells and caused cell death mainly through induction of apoptosis. Statistical analysis of the cells under a fluorescence microscope revealed significant differences in apoptotic cell populations between treated and untreated cells.
Conclusions: The results of this investigation indicated that the 4-chloro-5-iodo-7H-pyrrolo[2.3-d]pyrimidine compound does have cytotoxic effects on the K562 cell line. This information also revealed that this compound may initiate a new therapeutic standpoint for the treatment of leukemia.
Type of Study: Research |
Subject:
Hematology
References
1. Bridges AJ. Chemical inhibitors of protein kinases. Chem Rev 2001 Aug 8;101(8):2541-72. [DOI:10.1021/cr000250y] [PMID]
2. Al-Issa SA. Synthesis and anticancer activity of some fused pyrimidines and related heterocycles. Saudi Pharm J 2013 Jul 1;21(3):305-16. [DOI:10.1016/j.jsps.2012.09.002] [PMID] [PMCID]
3. Hajabbas Farshchi A, Afzal Ahangaran N, Valikhani A, Ghorbani S. The Effect of 2-Chloropyrimidine on K562 Cell Line. Stud Med Sci 2020; 31 (3) :188-98 [Google Scholar]
4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Am J Hematol;96(10):3343-56. [DOI:10.1182/blood.V96.10.3343.h8003343_3343_3356] [PMID]
5. Klein E, Vánky F, Ben‐Bassat H, Neumann H, Ralph P, Zeuthen J, et al. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Can 1976;18(4):421-31. [DOI:10.1002/ijc.2910180405] [PMID]
6. Moosavi MA, Yazdanparast R, Sanati MH. The cytotoxic and anti-proliferative effects of 3-hydrogenkwadaphnin in K562 and jurkat cells is reduced by guanosine. BMB Rep 2005;38(4):391-8. [DOI:10.5483/BMBRep.2005.38.4.391] [PMID]
7. Oslakovic, C. The regulation of blood coagulation by high-density lipoprotein particles. Skåne University Hospital, Lund University, 2010. [Google Scholar]
8. Andreasen CB, Latimer KS. Separation of avian heterophils from blood using Ficoll-Hypaque discontinuous gradients. Avian Dis 1989:163-7. [DOI:10.2307/1591082] [PMID]
9. Sahi S, Tewatia P, Ghosal S. Leishmania donovani pteridine reductase 1: comparative protein modeling and protein-ligand interaction studies of the leishmanicidal constituents isolated from the fruits of Piper longum. J Mol Model 2012;18(12):5065-73. [DOI:10.1007/s00894-012-1508-y] [PMID]
10. Korgaonkar KS, Ranade SS. Evaluation of acridine orange fluorescence test in viability studies on Escherichia coli. Can J Microbiol 1966 Feb 1;12(1):185-90. [DOI:10.1139/m66-024] [PMID]
11. Bank HL. Rapid assessment of islet viability with acridine orange and propidium iodide. In Vitro Cell Dev Biol Plant 1988;24(4):266-73. [DOI:10.1007/BF02628826] [PMID]
12. Dorsey JF, Jove R, Kraker AJ, Wu J. The pyrido [2, 3-d] pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000;60(12):3127-31. [Google Scholar]
13. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48(3):589-601. [Google Scholar]
14. Grzywacz B, Miller JS, Verneris MR. Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol 2008;21(3):467-83. [DOI:10.1016/j.beha.2008.07.008] [PMID] [PMCID]
15. Pacheco DY, Stratton NK, Gibson NW. Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line. Cancer Res 1989;49(18):5108-10. [Google Scholar]
16. Marshall MV, Marshall MH, Degen DR, Roodman GD, Kuhn JG, Ross ME, Von Hoff DD. In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units. Stem Cells 1993;11(1):62-9. [DOI:10.1002/stem.5530110111] [PMID]
17. Pacheco DY, Cook C, Hincks JR, Gibson NW. Mechanisms of toxicity of hepsulfam in human tumor cell lines. Cancer Res 1990 Dec 1;50(23):7555-8. [Google Scholar]
18. Dorsey JF, Jove R, Kraker AJ, Wu J. The pyrido [2, 3-d] pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000;60(12):3127-31. [Google Scholar]
19. Iwasaki K, MacKenzie EL, Hailemariam K, Sakamoto K, Tsuji Y. Hemin-mediated regulation of an antioxidant-responsive element of the human ferritin H gene and role of Ref-1 during erythroid differentiation of K562 cells. Mol Cell Biol 2006;26(7):2845-56. [DOI:10.1128/MCB.26.7.2845-2856.2006] [PMID] [PMCID]
20. 20 - Koiso Y, Nakajima O, Matsumura D, Fujimoto Y, Hashimoto Y. Chemical control of cell differentiation of human myeloleukemia K562 cell line. Yakugaku Zasshi: J Pharma Soc Japan 2000;120(1):104-12. [DOI:10.1248/yakushi1947.120.1_104] [PMID]
21. 21 - Sutherland JA, Turner AR, Mannoni P, McGann LE, Turc JM. Differentiation of K562 leukemia cells along erythroid, macrophage, and megakaryocyte lineages. J Biol Response Mod 1986;5(3):250-62. [Google Scholar]
22. Samad NA, Abdul AB, Abdullah RA, Ibrahim TA, Rahman H, Keong YS. Zerumbone (zer) induces apoptosis in Hepg2 cells via mitochondrial pathway. Int J Pharm Pharm Sci 2015;7:599-604. [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
